Form 4 for IDXX Idexx Laboratories
Accepted 2021-08-09 00:00:00 ET · period of report 2021-08-05 · accession 0001567619-21-014768 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-08-09 | 2021-08-05 | IDXX | Hunt Nimrata | EVP | M - OptEx | $137.90 | +538 | 8,644 | +7% | +$74.2K |
| D | 2021-08-09 | 2021-08-05 | IDXX | Hunt Nimrata | EVP | S - Sale+OE | $703.00 | -538 | 8,106 | -6% | -$378.2K |
| DM | 2021-08-09 | 2021-08-05 | IDXX | Hunt Nimrata | EVP | M - OptEx | — | -538 | 1,218 | -31% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-05 | M | A | 27 | $67.85 | 8,133.28 | D | — | — | (F1) Includes a total of 23.2845 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2021 and June 30, 2021. |
| 2 | Common | Common Stock | 2021-08-05 | M | A | 511 | $141.60 | 8,644.28 | D | — | — | |
| 3 | Common | Common Stock | 2021-08-05 | S | D | 538 | $703.00 | 8,106.28 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2021-08-05 | M | D | 27 | — | 0 | D | $67.85 · — to 2026-02-13 | 27 Common Stock | (F4) Not applicable. (F2) Grant of option to buy 1,940 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2017. |
| 5 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2021-08-05 | M | D | 511 | — | 1,218 | D | $141.60 · — to 2027-02-13 | 511 Common Stock | (F4) Not applicable. (F3) Grant of option to buy 3,579 shares of Issuer common stock that vest in five annual installments beginning on February 14, 2018. |